Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $958000.0.

  • Ernexa Therapeutics' Accounts Payables fell 5631.55% to $958000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $958000.0, marking a year-over-year decrease of 5631.55%. This contributed to the annual value of $1.7 million for FY2024, which is 6129.33% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Accounts Payables of $958000.0 as of Q3 2025, which was down 5631.55% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Accounts Payables registered a high of $3.7 million during Q2 2021, and its lowest value of $958000.0 during Q3 2025.
  • Moreover, its 5-year median value for Accounts Payables was $1.5 million (2022), whereas its average is $1.7 million.
  • Per our database at Business Quant, Ernexa Therapeutics' Accounts Payables soared by 26227.71% in 2021 and then plummeted by 5982.94% in 2022.
  • Over the past 5 years, Ernexa Therapeutics' Accounts Payables (Quarter) stood at $996262.0 in 2021, then surged by 62.61% to $1.6 million in 2022, then tumbled by 34.14% to $1.1 million in 2023, then skyrocketed by 61.29% to $1.7 million in 2024, then crashed by 44.33% to $958000.0 in 2025.
  • Its Accounts Payables was $958000.0 in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.